FGFR1 and Patent ductus arteriosus: Inaddition, we have confirmed using surface plasmon resonance (SPR) that bindingparameters for a close analogue of the canonical FGFR1 inhibitor PD173074 (ref.23; henceforth referred to as PDA; Fig. 1a; Supplementary Fig.1) are unaltered for the Asp623Ala mutant relative to the kinase-activeform (data not shown).